Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level

American Journal of Hematology

Volumn 83, Issue 3, 2008, Pages 226-232

  Oshima, Kumi ^a,b   Kanda, Yoshinobu ^a,b   Nakasone, Hideki ^a   Arai, Shunya ^a   Nishimoto, Nahoko ^a   Sato, Hiroyuki ^a   Watanabe, Takuro ^a   Hosoya, Noriko ^b   Izutsu, Koji ^a   Asai, Takashi ^a   Hangaishi, Akira ^a   Motokura, Toru ^a   Chiba, Shigeru ^b   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; CYCLOSPORIN; METHOTREXATE; PREDNISOLONE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; MALE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIVING DONORS; MALE; METHOTREXATE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 39749180389     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21087     Document Type: Article

References (23)

1. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT Bone Marrow Transplant 1997;19:759-764.
2. Yee GC, Self SG, McGulre TR, et al. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1968;319:65-70.
3. Przepiorka D, Shapiro S, Schwinghammer TL, et al. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: Association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant 1991;7:461-465.
4. Kanda Y, Hyo R, Yamashita T, et al. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am J Hematol 2006;81:838-844.
5. Martin P, Bleyzac N, Souillet G, et al. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003;32:777-784.
6. Ogawa N, Kanda Y, Matsubara M, et al. Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion. Bone Marrow Transplant 2004;33:549-552.
7. Miller KB, Schenkein DP, Comenzo R, et al. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 1994;68:15-20.
8. Grevel J, Welsh MS, Kahan BD. Cyclosporine monitoring in renal transplantation: Area under the curve monitoring is superior to trough-level monitoring, Ther Drug Monit 1989;11:246-248.
9. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993;54:205-218.
10. Duncan N, Craddock C. Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant 2006;38:169-174.
11. Nakamura Y, Takeuchi H, Okuyama K, et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. Transplant Proc 2005;37:1725-1727.
12. Kagawa Y, Sawada J, Yamada S, et al. Relationship between development of nephrotoxicity and blood concentration of cyclosporine A in bone-marrow transplanted recipients who received the continuous intravenous infusion. Biol Pharm Bull 2003;26:1115-1119.
13. Hiraoka A, Ohashi Y, Okamoto S, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001,28:181-185.
14. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000;96:2062-2068.
15. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92:2303-2314.
16. Wingard JR, Nash RA, Przepiorka D, et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant 1998; 4:157-163.
17. Yanada M, Emi N, Naoe T, et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplant 2004;34:331-337.
18. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991;77:1423-1428.
19. Bacigalupo A, Vitale V, Corvo R, et al. The combined effect of total body rradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantalion. Br J Haematol 2000;108:99-104.
20. Alvarez JS, Sacristan JA, Alsar MJ. Comparison of a monoclonal antibody fluorescent polarization immunoassay with monoclonal antibody radioimmunoassay for cyclosporin determination in whole blood. Ther Drug Monit 199214-78-80.
21. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-828.
22. Kanda Y, Mineishi S, Saito T, et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: A prospective evaluation. Transplantation 2002;73:568-572.
23. Gooley TA, Leisenring W, Crowley J. Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999;18:695-706.